In Parkinson's disease Long Treatment Syndrome (LTS) is a frequent and unpleasant feature of treatment with L-DOPA for long periods. In order to achieve the best effectiveness of treatment, different preparations of the drugs have been introduced: controlled release (CR), liquid rapidly-absorbed formulas. Therefore plasmatic L-DOPA monitoring represents an important tool in order to study and improve therapeutical strategies. 100 patients with Parkinson's Disease treated with L-DOPA underwent plasmatic drug monitoring and the authors underline the importance of this procedure in the choice of individualized therapeutic schemata.
|Translated title of the contribution||Plasmatic L-DOPA monitoring: Clinical use in Parkinson disease|
|Number of pages||5|
|Journal||Rivista di Neurobiologia|
|Publication status||Published - 1995|
ASJC Scopus subject areas